ABOUT

The XCR Diagnostics Story.

XCR Diagnostics, Inc. was founded in April 2015 with the goal of developing and delivering a simple, easy to use system to the molecular diagnostic near patient testing market. We started with the patented XCR® chemistry and initially developed a hand-held instrument around our XCR chemistry that utilized the camera on a mobile telephone to detect fluorescence signal generated via amplification in real time. Through iterative prototype development, we refined the amplification/detection system, including imbedding an optical detection system. Our latest generation system can accurately detect pathogens from clinical specimens in 7 to 10 minutes. We are finalizing test units of our Portable Nucleic Acid Testing System (pNATS™) for an upcoming FDA Clinical Trial.

We recognized the need for a user friendly consumable to accompany the instrument that could accept multiple specimen types. Therefore, we initiated development of a universal, fully integrated, Sample Delivery System (SDS) or consumable in parallel with the instrument development. One of the key benefits of the XCR chemistry is its robust resistance to standard amplification inhibitors, as compared to other amplification technologies, which enabled us to create a universal consumable allowing a multitude of patient specimen types to be placed directly into the pNATS instrument.

As founder of Fluoresentric, Inc., now a wholly owned subsidiary of XCR Diagnostics, Inc., Dr. Brian E. Caplin developed and patented the XCR chemistry between 2007 and 2008. Our pNATS system powered by XCR enables us ( elim –to do a lot of very creative ) to introduce a paradigm changing approach to nucleic acid testing. We are nearing the completed solution and look forward to bringing the next generation of molecular diagnostic testing to the laboratory and near patent testing environment providing clinicians faster results aiding their decisions for patient treatment.

Executive Team.

Mark Powelson,
President & CEO

Mr. Powelson has been involved in medical, biotech and diagnostic markets for 30 years. He joined XCR Diagnostics in May of 2015 as COO and was elevated by the Board to Director and Chief Executive Officer in April of 2016. Mr. Powelson previously held roles with large multinational companies as well as smaller entrepreneurial start up organizations. His experience includes sales, marketing, operations, project management, fund raising, business development, turn around operations and restarts as well as new product development and introductions to both domestic and international life sciences markets. Mr. Powelson served as the Vice President of Sales and Marketing for HandyLab, Inc. Prior to his position with HandyLab, Mr. Powelson served as Gen-Probe’s Vice President of Worldwide Sales. Powelson holds a Master in Executive Leadership from the University of San Diego and a BA in business, minor in Accounting from Otterbein College.

Brian Caplin, PhD,
CSO

Dr. Caplin is the founder of Fluoresentric, Inc. and inventor of XCR chemistry. He holds a bachelor degree from Wabash College and a doctorate in the field of biochemistry and molecular biology from Indiana University School of Medicine. He has over 20 years’ experience in the development of methodologies related to the detection and manipulation of specific genetic targets. His industrial experience includes developing and implementing the manufacture of oligonucleotides used in Roche LightCycler and other real-time PCR instruments. Dr. Caplin has maintained an active research effort, resulting in novel molecular diagnostic approaches to nucleic acid amplification and drug resistance screening.

Daniel P. Kolk, PhD,
Vice President of Clinical Development

Daniel Kolk, PhD, has over 20 years experience in product development of molecular diagnostics assays. He is an expert in isothermal and PCR chemistries, sample processing and integration of molecular diagnostic assays on automated platforms. He made key technical innovations in the development of the Gen-Probe Procleixs blood screening products as well as Gen-Probe’s HPV assay. He most recently led the team that developed and received FDA 510(k) approval of the Hologic Panther Fusion respiratory assays. He received his B.A. from UC San Diego and his Ph.D. from Arizona State University.

Christy Allensworth,
Vice President, Commercial Development

Ms. Allensworth joined XCR in 2018 as Vice President, Commercial Development. She brings over 30 years of experience in Clinical Diagnostics Sales, Marketing, Product Development and Commercialization. Over the last 10 years, she has been focused on molecular diagnostics, launching a number of sample-to-result systems.

Diraviam Kannan Thirugnanam,
Vice President, Operational Development

TDK is a results-oriented Technology Leader with over 26 year of experience in strategic Technology Management, Quality Assurance & Regulatory Affairs (QARA) and Program Management. He joined XCR Diagnostics in May, 2018 from Perfint Healthcare where he served as the Director, QARA, focusing on engineering, quality and regulatory aspects of their Planning & Targeting Product solutions. TDK holds an MS in Regulatory Affairs from George Washington University and a BE in Electrical and Electronics Engineering from Birla Institute of Technology and Science.

Board of Directors.

Mark Powelson

Mr. Powelson has been involved in medical, biotech and diagnostic markets for 30 years. He joined XCR Diagnostics in May of 2015 as COO and was elevated by the Board to Director and Chief Executive Officer in April of 2016. Mr. Powelson previously held roles with large multinational companies as well as smaller entrepreneurial start up organizations. His experience includes sales, marketing, operations, project management, fund raising, business development, turn around operations and restarts as well as new product development and introductions to both domestic and international life sciences markets. Mr. Powelson served as the Vice President of Sales and Marketing for HandyLab, Inc. Prior to his position with HandyLab, Mr. Powelson served as Gen-Probe’s Vice President of Worldwide Sales. Powelson holds a Master in Executive Leadership from the University of San Diego and a BA in business, minor in Accounting from Otterbein College.

Brian Caplin, PhD

Dr. Caplin is the founder of Fluoresentric, Inc. and inventor of XCR chemistry. He holds a bachelor degree from Wabash College and a doctorate in the field of biochemistry and molecular biology from Indiana University School of Medicine. He has over 20 years’ experience in the development of methodologies related to the detection and manipulation of specific genetic targets. His industrial experience includes developing and implementing the manufacture of oligonucleotides used in Roche LightCycler and other real-time PCR instruments. Dr. Caplin has maintained an active research effort, resulting in novel molecular diagnostic approaches to nucleic acid amplification and drug resistance screening.

Mark Bagnall,
Chairman

Mark Bagnall is chief operating officer, co-founder and a member of the Board of Directors of Naia Limited, an international drug development company. He has held senior management positions in the biotechnology industry for more than 20 years. Prior to founding Naia, he served as president, chief executive officer and a member of the Board of Directors of GenturaDx until its sale to Luminex Corporation. Before joining GenturaDx, Mr. Bagnall was executive vice president and a member of the Board of ADVENTRX Pharmaceuticals. Prior to ADVENTRX, he was chief financial officer of several public and private biotechnology companies where he managed public and private financings and completed several licensing transactions and mergers. Mr. Bagnall serves on the Board of Directors of Ativa Medical Corporation. Previously, he was one of the founders of the Association of Bioscience Financial Officers, an international organization of lifescience CFOs. Bagnall is a CPA and started his career in the high technology/biotechnology practice of Ernst & Young. Bagnall holds degrees from UC Berkeley Business School (now Haas School of Business). B.S., Business Administration. Phi Beta Kappa. 1979 California CPA, 1982.

Lynda Merrill

Global life sciences Senior Executive Lynda A. Merrill has built her 30+ year career legacy through her multi-national business skills in driving profitability and shareholder value. Merrill is currently a U.S. based strategic and tactical consultant focusing on pre-market and early market companies. She previously held roles with large multinational companies and smaller domestically based organizations, both private and public. Merrill’s experience includes living in and managing organizations in the United Kingdom, Europe, and total World for four companies – QIAGEN, Boehringer Mannheim, Gen-Probe and IDS. She was a member of the Senior Executive team that successfully took Gen-Probe from private to public company status in 2002. Lynda held a number of roles at Gen-Probe, including Vice President for Industrial Relationships and Vice President of World Wide Marketing and Sales. She successfully implemented global marketing and pricing strategies and grew product revenues from $96MM to $223MM in 2003. Education: University of Sussex, United Kingdom B.S., Medical Technology, Palm Beach Atlantic College, Palm Beach, FL, MBA.

Stephen Caplin

Mr. Caplin holds a bachelor degree from Indiana University School of Business and a doctorate of jurisprudence from Indiana University School of Law. He is admitted and continues to practice law in Indiana. He has served on the board of directors of Fluoresentric since its organization. He has also served on the board of directors of several closely held corporations.

Matt Gersper

Mr. Gersper graduated from the University of California – Davis where he studied Economics, ran track, and played football. Mr. Gersper dedicated his first two years after college to becoming a professional athlete, only to come up short with the unique distinction of being cut from three different teams, in three different leagues: Canadian, USFL, and NFL. Over the next 30 years, he focused on training himself to become a successful businessman. Mr. Gersper was given many opportunities to learn and gain expertise in the various functions required to start, grow, and lead successful businesses. Gersper has now shifted his focus from helping businesses to helping people. On January 16, 2014, he sold his previous company and dedicate his time and resources to researching and sharing best practices for happy living. He writes to inspire others to believe that a better self is always possible – today, every day, for the rest of their lives. At Happy Living, we are on a mission to improve the health and wellbeing of the world, one person at a time.

Bruce Chafin

Mr. Chafin was Senior VP Compliance and Ethics Vanguard Health Systems. 1998-2013. Vice President Compliance and Ethics ORNDA Health Systems 1995-1998. Senior Investigator Energy and Commerce Committee Oversight and Investigative Subcommittee, U.S. House of Representatives 1985-1995. Auditor General Accounting Office 1980-1985. Education: MBA University of Florida 1978-1979. BSBA University of Florida 1974-1977.

Our Awards.

innovation-award
molecular-med-tricon-logo
heathcare-heros

2015 Utah Innovation Award
Best in Bio-Tech/Life Science

2015 Molecular Medicine Tri Conference Most Promising Company

Utah Business Magazine
Healthcare Hero

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt